Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology.
Hopes and expectations for the use and utility of new, emerging biomarkers in drug development have probably never been higher, especially in oncology. Biomarkers are exalted as vital patient selection tools in an effort to target those most likely to benefit from a new drug, and so to reduce development costs, lessen risk and expedite developments times. It is further hoped that biomarkers can be used as surrogate endpoints for clinical outcomes, to demonstrate effectiveness and, ultimately, to support drug approval. However, I perceive that all is not straightforward, and, particularly in terms of the promise of accelerated drug development, biomarker strategies may not in all cases deliver the advances and advantages hoped for.
Carroll
Kevin J
KJ
AstraZeneca Pharmaceuticals, Global Clinical Function, Alderley Park, Macclesfield, UK. kevin.carroll2@astrazeneca.com
D054316:Biomarkers, Pharmacological; D002986:Clinical Trials as Topic; D015195:Drug Design; D023381:Endpoint Determination; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D018579:Patient Selection; D011379:Prognosis; D012107:Research Design
D054316:Biomarkers, Pharmacological